| Ytd | -31.73% | |
| 1y | 14.25% |
| Open | 4.41 | Prev Close | 4.29 | Low | 4.24 | High | 4.69 | Mkt Cap | 553.31M |
| Vol | 0.00 | Avg Vol | 2.11M | EPS | -0.61 | P/E | -7.23 | Forward P/E | -5.87 |
| Beta | 2.82 | Short Ratio | 6.37 | Inst. Own | 55.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.10 | 200-d Avg | 4.60 | 1yr Est | 10.83 |
AQST News
Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 milli
WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquest
Aquestive Therapeutics Inc. (NASDAQ:AQST) announced positive findings from human factors and pharmac
Aquestive Therapeutics reports positive study results for Anaphylm sublingual film, paving the way f
BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained
Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third
WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquest
WARREN, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquesti
Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. Th
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
Aquestive Therapeutics NASDAQ: AQST said it remains on track to resubmit its new drug application fo
U.S. stocks rose, with Dow Jones up 300 points. STAA shares surged after better-than-expected result
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the bus
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.07 per share versus the Zacks Con
Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 milli
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.07) per share which beat the a
WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquesti
WARREN, N. J. , May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aques
WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquesti
NEW YORK--(BUSINESS WIRE)---- $AQST #AQST--Faruqi & Faruqi, LLP, a leading national securities law f
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogniz
New York, New York--(Newsfile Corp. - May 4, 2026) - WHY: Rosen Law Firm, a global investor rights l
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
NEW YORK, May 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remind
New York, New York--(Newsfile Corp. - May 3, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationa
Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmac
Aquestive Therapeutics (NASDAQ:AQST) sees FY2026 sales of $46.000 million-$50.000 million vs $49.888
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.15) per share which missed the
Jim Cramer finds Aquestive Therapeutics very interesting, while Amphenol Corporation is a great stoc
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after t